Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis

J Ocul Pharmacol Ther. 2006 Feb;22(1):47-53. doi: 10.1089/jop.2006.22.47.


We assessed the efficacy of topical cyclosporin 0.05% ophthalmic emulsion versus tobramycin 0.3%/dexamethasone 0.1% in patients with posterior blepharitis. Posterior blepharitis improved significantly from the initial study visit with both cyclosporin treatment and tobramycin/dexamethasone. Cyclosporin provided greater improvements in Schirmer's scores (P < 0.001) and tear break-up time (P = 0.018) than tobramycin/dexamethasone after 12 weeks of treatment. Eyelid health also improved in both groups, but the mean improvement in meibomian gland secretion quality was significantly greater with cyclosporin than with tobramycin/dexamethasone (P = 0.015). Moreover, a higher percentage of patients in the cyclosporin treatment group had improvements in symptoms of blurred vision, burning, and itching and more cyclosporin-treated patients experienced resolution of lid telangiectasia. The findings in this prospective study suggest that posterior blepharitis can be more effectively treated with cyclosporin than with tobramycin/dexamethasone. These findings should be further evaluated in large-scale, controlled, clinical trials.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Blepharitis / drug therapy*
  • Blepharitis / pathology
  • Cyclosporine / administration & dosage*
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Prospective Studies
  • Tears / metabolism
  • Tobramycin / therapeutic use
  • Treatment Outcome


  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Ophthalmic Solutions
  • Dexamethasone
  • Cyclosporine
  • Tobramycin